Facebook Twitter
Now With Over 23,000 Reviews!
Sign up now

Zumiez Inc. (ZUMZ): Another Immediate Buy…

Sep 15, 2015

The last time I traded ZUMZ it just gapped from $30 to less than $24. Incredibly oversold reads on MACD, MFI and RSI got us in as the stock found solid footing. Close to 14 days later, I was out of the trade with a gain of 186% using the August 25 call options....

And I believe we can pull a similar gain, as the stock gaps down from $22.50 to $14 a share. Again, it’s oversold on MACD, RSI and MFI as seen below. And it’s only a matter of time before it pops higher…  I want in now. Consider buying the stock up to $15 and / or the ZUMZ November 2015 15 calls up to $1.35.

 

InterOil Corporation (IOC): Buy off the Lows

Sep 15, 2015

It's time to buy IOC again, as our technical pivot points become over-extended.

Plus, Goldman Sachs just added the stock to its Conviction Buy list with a PT of $45 a share. 

Consider buying the undelrying stock up to $38 and / or the IOC December 2015 35 calls at market.

 

 

How to Really Trade Biotech Stocks…

Sep 14, 2015

Most of us who use the FDA calendar and Phase III trial dates know one thing: The price of a biotech and pharmaceutical company will go up as the date in questions draws closer.

All we have to do is trade on the anticipation of news momentum.

For example, in early September 2015, foolish investors sent Collegium Pharmaceuticals (COLL) down from $20 to $13 on nothing.

It was now oversold on MACD, MFI and RSI… on nothing substantial.

So we bought, knowing the stock was very likely to move higher as it headed into its September 11 FDA advisory panel review… and quite possibly explode on prior news that the drug met its primary endpoint, which showed a statistically significant difference in average pain intensity from Randomization Baseline to Week 12 between the Xtampza ER and placebo groups, according to the latest press release.

And then it happened.

The drug was green-lighted by the FDA panel… and popped 39% in a day.

 

Restoration Hardware (RH): Screaming Off the Lows…

Sep 11, 2015

On September 2, I noted, “The stock is now setting up to reverse off recent lows at the 200-day moving average. Since late May 2014, the stock has held the same moving average well… and bounced. We’re betting on a similar move now. What makes this trade even better is that MFI, MACD and RSI are on the floor, ready to reverse from oversold conditions at any point.”

We just got that bounce…

The stock now trades $6.40 higher after strong earnings and strong growth prospects.

Even now, the stock remains oversold on MACD and reversing RSI. I’d like to see a test of $105 on the stock near-term.

 

Mastercard (MA): Buy, Buy, Buy…

Sep 10, 2015

I’ve been recommending a buy on MasterCard (MA) for years…

And I strongly believe the latest pullback on disappointing guidance may be a great buy opportunity here, as MACD tests an historical low of -1.3. The last time it got this low, MA popped from $70 to 87.50 not long after.

I don’t expect the fear or selling pressure to last much longer in the name based on the fact that this is MA. Long-term growth remains solid.

There are two ways to trade this. One, buy the underlying stock up to $92… and / or two, buy to open the MA January 2016 92 call up to $6. It has a current delta of 0.5064.

 

Page:   ... 64 ...